Sionna Therapeutics, Inc.
No SEC Form 4 filings for $SION in the last 30 days.
See all $SION insider activity →Raymond James raised its price target on Sionna Therapeutics (NASDAQ:SION) to $59 from $53 and kept a Strong Buy rating after the company’s Q2 2026 update. The stock trades at $50.26. The firm cited Phase 2a CF data for SION-719 (PreciSION CF) and upcoming summer readouts to guide a Phase 2b start in H2 2026.
Sionna Therapeutics (Nasdaq: SION) reported Q2 2026 results and updated its cystic fibrosis pipeline. It said enrollment is complete for the PreciSION CF Phase 2a trial of SION-719, with topline data expected in summer 2026, and that a Phase 1 dual-combination trial of SION-451 is also on track. Cash totaled $268.3M, expected to fund operations into 2028. R&D was $21.9M and net loss was $29.9M.
Sionna Therapeutics, Inc. (SION) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sion2q26earningsrelease_fi.htm EX-99.1 Document Sionna Therapeutics Reports Second Quarter 2026 Financial Results PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 202
Over the past 7 days, alphai's AI scored 3 news stories mentioning SION (Sionna Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent SION coverage spans insider activity, financial news and earnings.
Street PT lift is tied to upcoming cystic fibrosis readouts and a Phase 2a endpoint framework, supporting near-term sentiment but not de-risking biology yet.
Near-term catalyst is summer 2026 topline readouts, with cash runway extended into 2028, reducing near-term financing risk.
The filing updates cash runway and confirms near-term clinical catalysts, which can drive risk-on positioning in the name.
This is a routine insider sale under a pre-arranged 10b5-1 plan, with limited standalone signal for fundamentals.
This is a routine 10b5-1 insider sale disclosure; it may slightly pressure sentiment but does not change fundamentals by itself.
alphai scores every news story that mentions SION with an AI model for sentiment and relevance, and aggregates insider trades from Sionna Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Raymond James raised its price target on Sionna Therapeutics (NASDAQ:SION) to $59 from $53 and kept a Strong Buy rating after the company’s Q2 2026 update. The stock trades at $50.26. The firm cited Phase 2a CF data for SION-719 (PreciSION CF) and upcoming summer readouts to guide a Phase 2b start in H2 2026.
4 min readSionna Therapeutics (Nasdaq: SION) reported Q2 2026 results and updated its cystic fibrosis pipeline. It said enrollment is complete for the PreciSION CF Phase 2a trial of SION-719, with topline data expected in summer 2026, and that a Phase 1 dual-combination trial of SION-451 is also on track. Cash totaled $268.3M, expected to fund operations into 2028. R&D was $21.9M and net loss was $29.9M.
4 min readSionna Therapeutics, Inc. (SION) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sion2q26earningsrelease_fi.htm EX-99.1 Document Sionna Therapeutics Reports Second Quarter 2026 Financial Results PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 202
6 min readThompson Peter A. sold 85,918 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at $44.86 ($3.85M total) on 2026-07-07 under a Rule 10b5-1 trading plan.
1 min readORBIMED ADVISORS LLC sold 85,918 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at $44.86 ($3.85M total) on 2026-07-07 under a Rule 10b5-1 trading plan.
1 min readThompson Peter A. sold 115,844 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at $45.50 ($5.27M total) on 2026-06-30 under a Rule 10b5-1 trading plan.
2 min readORBIMED ADVISORS LLC sold 115,844 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at $45.50 ($5.27M total) on 2026-06-30 under a Rule 10b5-1 trading plan.
1 min readSionna Therapeutics, Inc. (SION) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. sion-20260617 0002036042 FALSE 0002036042 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________ FORM 8-K __________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
3 min readThompson Peter A. sold 101 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at $44.49 on 2026-05-27 under a Rule 10b5-1 trading plan.
2 min readJennifer Fitzpatrick, Chief Legal Officer of Sionna Therapeutics, sold 10,250 shares of common stock for $347,018 on March 5, 2026, after exercising options for an equal number of shares. The transactions were pre-arranged under a Rule 10b5-1 plan, resulting in Fitzpatrick directly owning zero shares. This mirrors recent positive analyst sentiment, with increased price targets and new coverage for Sionna Therapeutics, driven by strong financial guidance and upcoming proof-of-concept readouts for its NBD1 stabilizers.
3 min read
